GTBP
vs
S&P 500
GTBP
S&P 500
Over the past 12 months, GTBP has underperformed S&P 500, delivering a return of -81% compared to the S&P 500's +17% growth.
Stocks Performance
GTBP vs S&P 500
Performance Gap
GTBP vs S&P 500
Performance By Year
GTBP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
GT Biopharma Inc
Glance View
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in Brisbane California, California and currently employs 8 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The firm's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The firm is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).
